U.S. patent application number 15/536634 was filed with the patent office on 2017-12-28 for crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form.
This patent application is currently assigned to METRIOPHARM AG. The applicant listed for this patent is METRIOPHARM AG. Invention is credited to Josef Breu, Wolfgang Brysch, David Kosel, Beate Ludescher, Thomas Martin, Michael Niedermaier, Jorg Von Wegerer.
Application Number | 20170368063 15/536634 |
Document ID | / |
Family ID | 52133782 |
Filed Date | 2017-12-28 |
United States Patent
Application |
20170368063 |
Kind Code |
A1 |
Martin; Thomas ; et
al. |
December 28, 2017 |
CRYSTALLINE FORM OF 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE SODIUM
SALT, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AND METHOD
FOR THE PRODUCTION OF SAID FORM
Abstract
The invention relates to the provision of a new crystalline form
for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium, the use of
this form for medical purposes, methods for producing the
crystalline form according to the invention, as well as
pharmaceutical preparations comprising said form.
Inventors: |
Martin; Thomas; (Selb,
DE) ; Breu; Josef; (Bayreuth, DE) ; Brysch;
Wolfgang; (Berlin, DE) ; Kosel; David;
(Leipzig, DE) ; Ludescher; Beate; (Berlin, DE)
; Niedermaier; Michael; (Berlin, DE) ; Von
Wegerer; Jorg; (Berlin, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
METRIOPHARM AG |
Zurich |
|
CH |
|
|
Assignee: |
METRIOPHARM AG
Zurich
CH
|
Family ID: |
52133782 |
Appl. No.: |
15/536634 |
Filed: |
December 18, 2015 |
PCT Filed: |
December 18, 2015 |
PCT NO: |
PCT/EP2015/002555 |
371 Date: |
June 16, 2017 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/502 20130101;
A61P 37/06 20180101; A61P 9/10 20180101; A61P 37/02 20180101; C07D
237/32 20130101 |
International
Class: |
A61K 31/502 20060101
A61K031/502; C07D 237/32 20060101 C07D237/32 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 18, 2014 |
EP |
14004274.8 |
Claims
1. Crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt, characterized by crystallography values determined by
means of X-ray powder diagrams: d values: 13.131; 7.987; 7.186;
6-566; 6.512; 5.372; 3.994; 3.662; 3.406; 3.288; 3.283; 3.222;
3.215; 3.127; 2.889 and 2-theta values: 6.73; 11.07; 12.31; 13.48;
13.59; 16.49; 22.24; 24.29; 26.14; 27.10; 27.14; 27.67; 27.72;
28.52; 30.93.
2. The crystalline form according to claim 1, characterized by a
content of water of crystallization .ltoreq.0.4%.
3. A method for producing the crystalline form as defined in claim
1, characterized by solving of a
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt anhydrate in
DMSO, subsequent stirring of this solution until a suspension is
generated and subsequent drying of said suspension until DMSO is
completely evaporated.
4. The method according to claim 3 for the production of a
crystalline form as defined in claim 1, characterized by solving of
a 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt anhydrate in
DMSO at at least 90.degree. C., subsequent stirring of this
solution under maintenance of said temperature, until a suspension
is generated, and subsequent drying of said suspension at said
temperature until DMSO is completely evaporated.
5. The method according to claim 3 for the production of a
crystalline form as defined in claim 1, characterized by the
addition of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt
anhydrate in a ratio from 1-300 to 1-30,000.
6. The method according to claim 3 for the production of a
crystalline form as defined in claim 1, characterized by DMSO being
heated to at least 90.degree. C. before a
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt anhydrate is
added.
7. The method according to claim 3 for the production of a
crystalline form as defined in claim 1, characterized by applying a
vacuum after the initial dissolution step for further stirring and
the drying step.
8. The method according to claim 3 for the production of a
crystalline form as defined in claim 1, characterized by using a
temperature range from 70.degree. C. to 189.degree. C. for further
stirring and the drying step.
9. The method according to claim 3 for the production of a
crystalline form as defined in claim 1, characterized by the use of
a DMSO-H.sub.2O mixture for the initial dissolution step.
10. Pharmaceutical preparation, characterized by comprising the
crystalline form as defined in claim 1.
11. Pharmaceutical preparation according to claim 10, characterized
by the application or combination with other active ingredients,
adjuvants and/or standard therapies.
12. Pharmaceutical preparation according to claim 10, characterized
in that it may contain pharmaceutically acceptable excipients.
13. Crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt as defined in claim 1 for prophylactic or therapeutic
use in medicine.
14. Crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt as defined in claim 1 for prophylactic or therapeutic
use according to claim 13 as an immunomodulator.
15. Crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt as defined in claim 1 for prophylactic or therapeutic
use according to claim 13 in conditions with an excessive immune
response or in conditions with immunodeficient background.
16. Crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt as defined in claim 1 produced by the method as defined
in claim 9 for use in a topical application.
Description
TECHNICAL FIELD OF THE INVENTION
[0001] The present invention relates to the provision of a new
crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium
salt with advantageous properties, pharmaceutical preparations
containing the same, and methods for producing the same.
[0002] The invention in particular relates to the provision of a
new crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt for medical purposes.
BACKGROUND OF THE INVENTION
[0003] For quite some time chemical compounds having
immunomodulatory effects are known in the art. To these compounds
also belongs 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt.
This compound is known from EP 1 203 587 A and has the following
basic structure (Na.sup.+ not shown):
##STR00001##
[0004] The above basic structure is also called luminol. Other
common synonymous terms are 3-aminophthalhydrazide, 3-aminophthalic
hydrazide, o-aminophthalhydrazide and o-aminophthalic hydrazide. It
is known from prior art that
5-amino-2,3-dihydrophthalazine-1,4-dione alkali salts crystallize
as solids in different hydrate forms. In prior art, in particular
the dihydrate of the sodium salt (RU2113222C1) and a trihydrate of
the potassium salt and mixed forms thereof (RU2211036C2) are
described. In addition, crystal structures of
5-amino-2,3-dihydrophthalazine-1,4-dione alkali salts partially
differing in their hydration stage are known from scientific
literature. A structural characterization is provided for a
potassium salt anhydrate, a lithium salt monohydrate, a rubidium
salt dihydrate, a caesium salt trihydrate and a sodium salt
hexahydrate (cf. Guzei et al. (2013): Journal of Coordination
Chemistry, 66:21, 3722-3739). Also a dihydrate as well as two
polymorphic anhydrates of the sodium salt have been characterized
structurally. The characterization was conducted from mixtures
containing either both of said anhydrate forms or all three forms
(cf. Rybakov et al. (2014): Crystallography Reports, 59,
383-393).
[0005] Pure crystalline forms of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt anhydrate were
first described in WO2011/107295A1 as form I and form II. The
crystalline forms disclosed in WO2011/107295A1 were characterized
by a X-ray powder diffractogram, expressed in D or 2-theta values,
whereas "D" represents interplanar spacings and "2-theta"
represents the 2-theta angles in degrees. The interplanar spacing D
(also d) describes the vertical distance between two consecutive
lattice planes. The Bragg angle theta (.theta.) indicates the
characteristic angle resulting of the reflection of the incident
X-ray beam at a lattice layer of the crystal, thereby producing a
X-ray diffraction pattern. Both parameters are linked via the Bragg
formula:
n.lamda.=2d sin(.theta.).
By these characteristic values d and .theta. a crystal is
characterized necessarily and sufficiently.
[0006] D-values were disclosed in WO2011/107295A1 with
13.5; 6.9; 5.2; 4.6; 3.9; 3.5; 3.4; 3.3; 3.1 and 3.0 for form I;
and with 12.9; 7.9; 7.1; 6.5; 5.3; 4.0; 3.7; 3.6; 3.3 and 3.2 for
form II.
[0007] 2-theta-angles were disclosed with
6.5; 12.7; 16.9; 19.3; 22.8; 25.8; 26.6; 27.2; 28.7 and 30.3 for
form I; and with 6.8; 11.2; 12.5; 13.7; 16.7; 22.4; 24.3; 24.9;
27.2 and 27.8 for form II.
[0008] In addition, the relative intensities of the reflections
were reported.
[0009] WO2011/107295A1 also lists a number of rather complex
methods of production for both form I as well as form II.
[0010] It is known in the art that crystalline forms of a substance
can differ in their physical properties such as solubility,
dissolution rate, and stability (cf. Haleblian und McCrone (1969):
Journal of Pharmaceutical Sciences, 58:911-929). Such properties
can affect the pharmaceutical processing of the active ingredient
as well as its biological availability and pharmacokinetics, and
thus its biological efficacy (cf. Griesser (2006) in: Polymorphisms
in the Pharmaceutical Industry. Hilfiker (Ed.) 211-234). For the
production of medicines it is important that the starting material
is stable, not hygroscopic and controllable in its behavior as a
solid during the complete production process. Further, the chemical
stability and solid-phase stability (phase purity) with long
storability of an active ingredient is extremely important (cf.
Miller et al. (2006) in: Polymorphisms in the Pharmaceutical
Industry. Hilfiker (Ed.) 385-403). It is desirable that even over a
longest possible storing time the physical properties of the active
ingredient will be maintained. This relates e.g. to the
hygroscopicity, solubility or initial dissolution rate of the
active ingredient, but also to phase purity.
[0011] Very important for the pharmaceutical processing and the
medical use are production methods which reliably and reproducibly
permit the production of the desired crystalline forms. When
producing crystalline forms, it should be considered that even
small deviations of the process parameters will cause changes of
the crystal structure of the products and can thus finally lead to
different crystalline forms or mixed forms. Properties changed
thereby--for instance a modified biological efficacy by a different
solubility--may lead to a rejection of complete batches. Often it
is not possible at all to produce the desired form (cf. Ulrich und
Jones (2005): Nachrichten aus der Chemie 53:19-23). Besides phase
purity of the active ingredient and the resulting possible changes
in the efficacy further important properties for the pharmaceutical
processing can be affected in an adverse manner, e.g. the
capability to be pressed to tablets by an impairment of the
pourability or of the flow rate of the crystalline form.
[0012] 5-amino-2,3-dihydrophthalazine-1,4-dione alkali salts belong
to the group of aminophthalhydrazides and are described in prior
art as immunomodulators with specific anti-inflammatory,
antioxidative and antitoxic properties (cf. WO2011/107295A1, U.S.
Pat. No. 6,489,326B1; EP0617024B1, U.S. Pat. No. 5,512,573A, U.S.
Pat. No. 5,543,410A, U.S. Pat. No. 7,326,690B2).
[0013] Immunomodulatory substances are commonly classified
according to their effects into immunosuppressants and
immunostimulants (cf. Rote Liste Service GmbH (2014):
www.rote-liste.de, access on Sep. 2, 2014). The corresponding
preparations with an exclusively immunosuppressive or an
exclusively immunostimulatory effect, such as immunosuppressive TNF
alpha blockers or immunostimulatory interferon beta preparations,
often cause significant undesired side effects in the organism,
actually because of their very specific mode of action. Some known
immunosuppressive substances, such as the TNF alpha blocker
adalimumab, specifically inhibit certain inflammatory mediators.
Such therapies are known to have serious side effects (cf. Descotes
(2008): Expert Opin. Drug Metab. Toxicol., 4:12:1537-1549), since
the blocking of individual inflammatory mediators is a severe
intervention into the complex immune system. For instance, in the
case of adalimumab opportunistic infections such as sepsis occur
frequently, occasionally malign lymphoma can occur as well.
Consequently the organism is not capable anymore to fulfil its
functions, hence reacting automatically and physiologically in an
appropriate manner to exogenous and endogenous inflammatory stimuli
such as bacterial infections. Thus, for instance, the application
of TNF alpha blockers is contraindicated in the case of serious
infections, this applies in particular for sepsis and tuberculosis.
Before administering a corresponding medication, e.g. for the
treatment of rheumatoid arthritis, a TBC screening is strongly
recommended. Moreover, Hoffmann (2005: Intensivmed 42:371-377)
could clearly demonstrate that TNF alpha blockers are not suitable
for the clinical application in case of septic conditions, but to
the contrary may even lead to an increased mortality.
[0014] The particular pharmacologic properties of the
5-amino-2,3-dihydrophthalazine-1,4-dione alkali salts are, however,
very useful, a.o. for the prevention of so-called cytokine storms
caused by excessive immune responses. In contrast to the so-called
cytokine blockers these salts are mostly free of side effects since
an inhibition of individual cytokines will not take place, but
these are regulated to a physiological level, and thus an adequate
reaction of the organism to infectious pathogens is assured further
on. Correctly speaking, the term to use in this case should be
immunoregulators instead of immunomodulators.
SUMMARY OF THE INVENTION
[0015] In the manufacture of medicinal products, in particular
concerning the dosing of active ingredients in pharmaceutical
preparations, the bulk density as a substance property plays a
major role. In particular too low bulk densities can cause problems
in the production process, ranging from poor flow properties to
difficulties in the exact dosing. Another common problem with
medicinal products, particularly in case of polymorphic agents, is
to maintain phase purity of the active ingredient over a longer
period of time (shelf life). In particular in pharmaceutical
preparations which include the risk of wetting of the active
substance with solvents, as it may be the case e.g. in tablets,
creams, lotions or emulsions, the risk of a solid phase transition
is particularly high, especially within the shelf life that for
economic reasons is as long as possible.
[0016] Task of the present invention was to provide a new anhydrate
form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt having
advantageous characteristics, in particular an improved storage
ability and/or an improved bulk density, that thus can be used
specifically for medical, particularly anti-inflammatory and
immunoregulatory purposes. Furthermore, the provided form shall
have physicochemical properties, which are advantageous for
medicinal products manufactured, stored and/or applied therewith,
individually or in combination.
[0017] The task was solved by the provision of a novel anhydrate
form for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt (form
III), which, based on experimental data of physicochemical and
biological characteristics, surprisingly and verifiably contrasts
with prior art and in particular contrasts with anhydrate forms I
and II of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt as
disclosed in WO2011/107295A1.
[0018] The crystalline anhydrate form III (form III) is defined by
15 characteristic values each of interplanar spacings and 2-theta
angles (see Table 1) expressed in a X-ray powder diffractogram
(FIG. 1). Form III is further defined by a structure solution and
Rietveld refinement from XRPD data using the TOPAS Academic
software (Tab. 2) resulting in the crystalline structure with the
respective packing motifs (FIG. 2), as well as by a solid
state-FT-IR spectrum (FIG. 3) and a Raman spectrum (FIG. 4).
[0019] Differences concerning physical characteristics between the
form according to the invention and the pure anhydrate forms of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt as disclosed
in prior art exist for example in bulk density and storage ability.
Compared to form I and II the form III according to the invention
is characterized by both an improved bulk density and also an
improved storage ability, wherein the bulk density of individual
batches of form III according to the invention is higher than 150
kg/m.sup.3, preferably higher than 175 kg/m.sup.3, mostly preferred
higher than 200 kg/m.sup.3, and wherein the storage ability refers
in particular to the maintenance of phase purity, preferably in
situations where wetting--intentionally or unintentionally--may
happen, wherein already low amounts of solvent can cause a partial
phase transition.
[0020] Further, the inventors have set themselves the task to
provide one or more methods for producing the novel anhydrate form
of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt according
to the invention in a feasible, economical and reproducible
way.
[0021] The illustrated methods shall preferably be carried out
without the use of heavy metal catalysts and shall permit the
reproducible production of the novel crystalline form III also for
any desired batch size.
[0022] This task was solved by the methods according to the
invention for producing crystalline form III. In one method
according to the invention initially any form for
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt anhydrate is
produced and afterwards completely dissolved in DMSO (dimethyl
sulfoxide) while stirring. DMSO is evaporated until a suspension
occurs, the suspension is then dried up. This method according to
the invention can be used for any desired batch size. The
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt used as
starting material for the production should be as pure as possible.
It can be produced, for example, by reduction of 3-nitrophthalic
acid in alkaline medium using a suitable reducing agent via
3-nitrophthalanhydride. Optional purification steps by
recrystallization may follow. Furthermore, a particularly
advantageous method for producing anhydrate form II for
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt anhydrate is
presented.
[0023] The present invention finally comprises the use of form III
for medical purposes as a single agent or in combination with one
or more other active ingredients, as well as pharmaceutical
preparations containing form III alone or in combination with one
or more other active ingredients.
DETAILED DESCRIPTION
[0024] Unless otherwise shown, the technical and scientific terms
used in the present invention have the meaning that a person
skilled in the relevant technical art will attribute to them.
Definitions
[0025] "Form 1" and "form II" are crystalline forms of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt known from
WO2011/107295A1. To enhance readability these terms will be
maintained.
[0026] "Form II" is a crystalline form of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt according to
the invention.
[0027] The terms "medicine" and "for use in medicine" refer to both
human medicine and veterinary medicine.
[0028] The term "active ingredient" in a broader sense comprises
each pharmacologically active component of a medical product. An
active ingredient can be applied alone--as a single agent--or in a
pharmaceutical preparation.
[0029] An "organism" in the scope of the present invention is a
form of animal life, in particular human, pet or livestock.
[0030] The term "pharmaceutical preparation" or "pharmaceutical
composition" comprises the active ingredient according to the
invention in any pharmacologically suitable defined dose and dosage
form and at least one pharmaceutically acceptable excipient. The
term can also comprise further active ingredients alone or in
combination.
[0031] The term "excipient" is used herein to describe any
component of a pharmaceutical preparation besides the active
ingredient itself. The choice of a suitable excipient depends on
factors such as route of administration and dose as well as on the
influence on solubility and stability of the preparation by the
excipient itself. Pharmaceutical excipients are substances that are
known to the person skilled in the art or can be obtained from
standard pharmaceutical textbooks or official pharmacopeias (e.g.
European pharmacopeia). Examples for excipients comprise: carriers,
adjuvants, additives in general and especially fillers (basis),
coatings, lubricants, glidants, releasing agents, flow regulators,
humectants, rapid dissolution agents, disintegrants, sweeteners,
aromas, flavor modifiers, flavors, preservatives, dispersants,
coloring agents, solvents, solubilizers (wetting agents) and
dissolution retardants, absorption enhancers and absorption
retardants (retard preparations), penetration enhancers, diluents,
gel forming agents, thickening agents, binders, absorbents,
flavoring agents, aromatic substances, antioxidants, surfactants,
emulsifiers, triglycerides, pH regulators (buffers), fatiquors,
consistency enhancers, hydrotropes and substances producing gas
when chemically reacting with water.
[0032] "Adjuvants" are excipients which (are able to) enhance the
effect of the active ingredient such as solubilizers, surfactants,
absorption enhancers and penetration enhancers.
[0033] The terms "buffer", "buffer system" and "buffer solution"
refer to the ability of a system, in particular of an aqueous
solution, to withstand a pH change due to the addition of an acid
or a base or due to dilution with a solvent within the range
provided by the respective buffering capacity.
[0034] The term "disintegrant" refers to materials which are added
to a composition so that it can be broken apart more easily (e.g.
tablets) or swells more easily.
[0035] The term "binder" refers to materials which are added to a
composition for gluing together the single substances contained in
the composition, in particular solids with a fine degree of
dispersion or for gluing together with another composition, or with
a base.
[0036] The term "lubricant" refers to substances which are added to
the dosage form to facilitate the removal of tablets, granulates
etc., e.g. from a mold or nozzle after pressing by reducing
friction or abrasion.
[0037] "Glidants" are materials which prevent caking and improve
the flow properties of the individual components of the
composition, so that the flow is smooth and homogenous.
[0038] "Coloring agents" or "dyes" are auxiliary agents providing
color to the composition or dosage form.
[0039] The term "free from phase shift" or "phase purity" means
solid phase purity of a polymorphic active ingredient of at least
90%, preferred of at least 95%, particularly preferred of at least
98%, mostly preferred of at least 99%.
[0040] The term "effect" describes any intrinsic mode of action of
an active ingredient.
[0041] The term "shelf life" or "storage ability" describes the
stability, in particular the maintenance of phase purity, of an
active ingredient as single substance and/or in a pharmaceutical
preparation.
New Crystalline Form III of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt
[0042] The present invention includes a new crystalline anhydrate
form (form III) of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium
salt characterized by an x-ray powder diffractogram of a
Bragg-Brentano diffractometer (STOE STADI P) provided with a
DECTRIS MythenlK detector using mono-chromatized
(Ge111-monochromator) copper emissions Cu K(.alpha.1) (wave length
.lamda.=1,54187 .ANG.) and expressed in D or 2-theta values (Table
1), whereas "D" represents interplanar spacings and "2-theta"
represents the 2-theta angles in degrees. I/I.sub.o represents the
relative intensities of the reflections, in Table 1 presented both
in percent (%) and in a ordinal scale (rel).
TABLE-US-00001 TABLE 1 D values, 2-theta values and relative
intensities I/I.sub.o for Form III D 2-theta I/I.sub.o (%)
I/I.sub.o (rel) 13.131 6.73 100.00 vst 7.987 11.07 3.84 vw 7.186
12.31 10.06 w 6.566 13.48 5.07 w 6.512 13.59 25.59 m 5.372 16.49
11.21 w 3.994 22.24 2.43 vw 3.662 24.29 22.51 m 3.406 26.14 15.19 m
3.288 27.10 41.04 w 3.283 27.14 10.62 w 3.222 27.67 44.69 st 3.215
27.72 19.65 m 3.127 28.52 3.20 vw 2.889 30.93 4.80 w given that: vw
= very weak (0% < I/I.sub.0 .ltoreq. 5%) w = weak (5% <
I/I.sub.0 .ltoreq. 15%) m = medium (15% < I/I.sub.0 .ltoreq.
35%) st = strong (35% < I/I.sub.0 .ltoreq. 75%) vst = very
strong (75% < I/I.sub.0 .ltoreq. 100%)
[0043] Anhydrate form III is further characterized by
crystallographic data (cell parameters of the unit cell, crystal
system, space group) (Table 2) as well as by the crystalline
structure and the respective packing motifs, displayed as
ball-and-stick model and as calotte model (FIG. 2). Whilst calotte
models--due to the space-filling display of the atoms--create a
three-dimensional rendition of the molecules and thus their
orientation alongside the viewed direction in space (unit cell
axes) becomes apparent, ball-and-stick models--due to the waiver of
a space-filling display--allow a better in-depth view into the
inner structure. The structure solution and Rietveld refinement has
been conducted from XRPD data, recorded at a Bragg-Brentano
diffractometer (STOE STADI P) provided with a DECTRIS MythenIK
detector using mono-chromatized (Gel111-monochromator) copper
emissions Cu K(.alpha.1) (wave length .lamda.=1,54187 .ANG.), using
the software TOPAS Academic.
TABLE-US-00002 TABLE 2 Data on structure solution and Rietveld
refinement of form III from XRPD data (numbers in brackets
represent the standard deviations of the respective value):
Chemical formula C.sub.8H.sub.6N.sub.3NaO.sub.2 Molar mass [g/mol]
199.15 Crystal system monoclinic Space group P 2.sub.1/c Axis
lengths of the unit cell a [.ANG.] 8.0364(2) b [.ANG.] 3.69765(5) c
[.ANG.] 26.4246(7) Angles between the axes of the unit cell .alpha.
[.degree.] 90 .beta. [.degree.] 96.346(2) .gamma. [.degree.] 90
Volume of the unit cell V [.ANG..sup.3] 780.416(33) Number of
formula units per unit cell/ Z/Z' 4/1 Number of formula units per
asymmetric unit Packing density (volume of all atoms .rho. [g
cm.sup.-3] 1.69491(7) in the cell/volume unit cell) Structure
factor of zeroth order F(000) 408 (for h = k = l = 0). Measurement
temperature [.degree. C.] 295(2) Data range [.degree.2.theta.]
3-80.085 Reflections used 481 Refined parameters 66 Quality factors
(residual values, R-factors) R.sub.p 0.0214 of the structure
refinement: R.sub.wp 0.0296 R.sub.exp 0.0104 R.sub.Bragg 0.0148
[0044] In case of X-ray experiments the non-dispersive structure
factor F(000) specifies the number of electrons per unit cell. The
quality factors R.sub.p and R.sub.wp refer to the goodness-of-fit
between the calculated and the measured XRPD profile. R.sub.exp
represents the lowest possible value of R.sub.wp that can be
obtained when applying the theoretical structure model and the
number of refined parameters. R.sub.Bragg refers to the accuracy of
the refined structure model with regard to the extracted reflection
intensities.
[0045] Form III according to the invention is further characterized
by a solid state FT-IR spectrum, created with a JASCO FT/IR 6100
FT-IR spectrometer, provided with a DLATGS detector. The spectrum
is expressed by graphically plotting the measured transmission in %
and the respective wave number (FIG. 3).
[0046] Form III according to the invention is further characterized
by a Raman spectrum, created with a LabRam spectrometer with a
resolution of 2 cm.sup.-1, provided with a helium-neon laser (wave
length 628.8 nm) and a 100.times. lens. The spectrum is expressed
by graphically plotting the measured relative intensities in % and
the respective wave-number in cm.sup.-1 (FIG. 4).
[0047] The anhydrate form III according to the invention preferably
exhibits a content of water of crystallization of .ltoreq.0.4%.
Advantageous Physical Properties:
[0048] Surprisingly the inventors found that form III has
advantageous physical properties for pharmaceutical processing and
application, including thermostability, storage ability,
solubility, bulk density, crystal form and phase purity. These are
advantageous for the pharmaceutical production and further
processing in comparison to for example hydrates (di-, tri- and
hexahydrate), in which changes in water content can occur and thus
formulation problems, for example due to weight changes of the
active ingredient during tablet pressing, encapsulation or
sterilization.
[0049] For use in medicine form III is advantageous over the mixed
forms described by Rybakov et al. (2014: Crystallography Reports,
59, 383-393) because for pharmaceutical applications pure forms
always are preferable over mixed forms as they can be better
characterized and standardized. This is particularly important as
different polymorphs can have different pharmacokinetic properties
and thus a consistent bioavailability cannot be guaranteed in mixed
forms.
[0050] The form according to the invention can be distinguished
from known forms I and II by scanning electron microscopy: Form II
primarily exhibits needle-like crystallites of octahedral structure
with a length of several micrometers, which are built in layers; in
the SEM of form II there are mainly morphologically inconsistent
crystallites with rounded edges agglomerating in a powdery manner.
The form III according to the invention also exhibits rather
needle-like crystallites, however, in contrast to form II these
crystallites have rounded edges at their tips (FIG. 5).
[0051] From its crystal form advantageous properties for the
pharmaceutical processing arise for the form according to the
invention: Due to their needle-like crystalline particles form II
and form III are thus more suitable for direct tablet pressing. As
crystallites of the form III according to the invention are
significantly smaller than those of form II they provide--analogous
to form I--an improved pourability and thus an improved
filterability, as it is the case for form II. Also the bulk density
of form III according to the invention is significantly higher than
for form II (see Example 1).
[0052] It can thus be stated that form III according to the
invention combines in itself the respective advantages of form II
against form I and of form I against form II. Therefore form III
has physical properties which provide a great advantage in the
technical manufacture of medicinal products, in particular for the
production of solid preparations such as tablets, capsules and
powder. However, also within the scope of the production of liquid
preparations these characteristics offer advantages due to the
better manageability of the active ingredient according to the
invention during the manufacturing process. Of particular note in
this regard is the so called Hausner ratio, the quotient of bulk
density and tapped bulk density. The closer the Hausner ratio is to
1 the less problems in controlling the dosing accuracy are to be
expected. In particular for active ingredients with a big bulk
volume, hence a low bulk density, one has to expect a significant
difference between bulk volume and tapped bulk volume is to be
expected, and accordingly the Hausner ratio is high. Otherwise,
further steps subsequent to the production may become necessary, as
e.g. grinding, air-flow crushing or sieving are thus not necessary
for form III according to the invention. The provision of the
hereto suitable equipment according to GMP requirements becomes
irrelevant, and--generally expensive--production time is saved.
This is a clear economic advantage.
[0053] As already described in WO2011/107295A1 for anhydrate forms
form I and form II, the anhydrate form according to the invention
also exhibits a very high thermostability with decomposition
temperatures far above 300.degree. C. Thus the decomposition of
form III first starts from a temperature of 391.7.degree.
C..+-.10.degree. C. The determination was carried out by means of
simultaneous thermogravimetry (differential scanning calorimetry)
at a Linseis L81-077 coupled with mass spectroscopy measurements
with a Netzsch STA 449 C (thermobalance) with MS and FTIR coupling
over 30-600.degree. C. under synthetic air (4 N.sub.2:1 O.sub.2)
and a heating rate of 10.degree. C./min. The data were analyzed
with the company software Proteus.
[0054] The thermoanalytical data confirm the assumption made by the
inventors that crystalline form III as well as forms I and II
exhibit advantageous characteristics with regard to stability and
storage ability over the dihydrate having a solid phase transition
at 85.degree. C. (WO2011/107295A1). Also for other hydrates (e.g.
trihydrate, hexahydrate) it is to be expected that a solid phase
transition already starts below 100.degree. C. This property
further fosters the pharmaceutical processing of the crystalline
form according to the invention by rendering said form insensitive
to procedural steps with a high energy input, e.g. sterilization or
grinding. In the manufacture of an active ingredient which allows
terminal sterilization the GMP requirement of an closed sterile
production over all procedural steps does not apply. This is a
significant cost advantage.
[0055] The individual forms are also distinct from each other due
to the different stoichiometric coordination of the sodium cation
and the 5-amino-2,3-dihydrophthalazine-1,4-dione anion. Whilst in
form I a sodium cation is coordinated by in total 6
5-amino-2,3-dihydrophthalazine-1,4-dione anions in a trigonal prism
there are only 5 5-amino-2,3-dihydrophthalazine-1,4-dione anions in
form II and III.
[0056] By use of Pauling's rules (cf. Linus Pauling (1929): Journal
of the American Chemical Society, 51, 1010-1026) statements on the
stability of ionically built crystal structures a.o. can be made.
The third rule says that the occurrence of shared edges and
particularly faces decrease the stability in the coordination
polyhedra. Background to this is the electrostatic repulsion of
cations which increases when the distance is reduced. Thus the
sharing faces of the coordination polyhedra of adjacent cations in
a crystal structure leads to a smaller distance between them than
the sharing edges or corners of the coordination polyhedra.
[0057] In form I a sodium cation is coordinated by in total 6
5-amino-2,3-dihydrophthalazine-1,4-dione anions in a trigonal
prism. This coordination leads to a face-bridging to two adjacent
prisms, respectively, and to an effective distance of 3,395 .ANG.
between two adjacent sodium cations. In forms II and III a sodium
cation is coordinated by 5 5-amino-2,3-dihydrophthalazine-1,4-dione
anions with sharing edges with two directly adjacent polyhedra,
respectively. This leads to an effective distance of 3.510 .ANG.
between two adjacent sodium cations in form II, and 3.578 or 3.595
.ANG. between two adjacent sodium cations in form III,
respectively.
[0058] Based on the third Pauling's rule and on the effective
distances of the sodium cations it can therefore be assumed that
the coordination of form III is more stable than the respective
coordinations of form II and form I.
[0059] Moreover, crystalline form III appears substantially stable
with regard to a change in the water content, therefore formulation
problems due to weight changes of the active ingredient during
subsequent pharmaceutical processing (e.g. tablet pressing,
encapsulation) arise clearly less frequent.
[0060] The new crystalline form displays a further advantage over
the prior art because the lower maximum solubility (Example 2)
provides advantages in cases where a delayed release of the active
ingredient is aimed at. Form III is thus particularly suitable for
use in pharmaceutical preparations for oral and topical
applications, in particular tablets, capsules, cremes, powders and
special retard formulations for applications in which a delayed
release of the active ingredient is desirable.
[0061] Based on the results of "slurry" experiments (Example 3) it
is to be expected that form III under normal storage conditions at
room temperature is more resilient to transformation processes than
form I and form II. According to GPP such transformation processes
should only occur to a very small extent, or preferably not at all.
Due to this advantage the storage ability (shelf life) of a medical
product comprising form III is significantly increased, thus the
usability and the value for the producing and/or distributing
pharmaceutical industry is increased significantly. Furthermore,
the demands on technical effort regarding storage are thus
significantly decreased.
Example 1: Bulk Density
[0062] To compare bulk densities pure forms of the dihydrate and of
form I, II and III were produced. Anhydrate form I for
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt produced
according to the methods of WO2011/107295A1 served as starting
material for the recrystallizations.
Production:
[0063] For the production of the dihydrate 10 g of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt were solved in
100 mL H.sub.2O (demineralized) while stirring at room temperature
until apparently there was no more turbidity. Subsequently, 900 mL
2-propanol were added to the solution. After the beginning
precipitation the generated suspension was stirred for further 4 h.
The suspension was filtered under vacuum utilizing a Buchner
funnel. The remaining crystalline solid was dried at RT to constant
mass.
[0064] The production of form I of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt was carried
out by solving 10 g of 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt in 100 mL H.sub.2O (demineralized) while stirring at
room temperature until apparently there was no more turbidity. 900
mL 2-propanol were added to the solution. After the beginning
precipitation the generated suspension was immediately filtered
under vacuum utilizing a Buchner funnel. The remaining crystalline
solid was dried at RT to constant mass.
[0065] The production of form II for
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt was carried
out by solving 10 g of 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt in 100 mL H.sub.2O (demineralized) while stirring at
room temperature until apparently there was no more turbidity. 900
mL 2-propanol were added to the solution. After the beginning
precipitation the generated suspension was stirred for further 4 h.
The suspension was filtered under vacuum utilizing a Buchner
funnel. The remaining crystalline solid was dried at 60.degree. C.
in a drying cabinet to constant mass.
[0066] The production of form III of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt according to
the invention was performed as in production example 2--embodiment
1. 10 g of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt
were solved in 3.3 L DMSO while stirring at 90.degree. C. until
apparently there was no more turbidity. The solution was further
stirred by applying a vacuum (8.times.10.sup.-3
mbar.+-.1.times.10.sup.3 mbar) at 90.degree. C. until a suspension
was generated. The suspension was dried at 90.degree. C. under
vacuum (8.times.10.sup.-3 mbar.+-.1.times.10.sup.-3 mbar) until a
solid was generated. The solid was suspended in 2-propanol and
filtered under vacuum utilizing a Buchner funnel. It was rinsed
twice with 2-propanol. Subsequently, the crystalline solid was
dried at 50.degree. C. in a drying cabinet to constant mass.
[0067] After drying all forms produced were vortexed for 1 minute
to let bigger agglomerates carefully disaggregate.
Measurement of Bulk Density:
[0068] To determine the bulk density of the dihydrate and of forms
I and II as well as of form III according to the invention a hollow
glass cylinder (height: 20 mm, diameter: 20.5 mm, volume: 6.601
cm.sup.3; in the following referred to as "collecting vessel") with
removable bottom was used. A sample of each of the respective
solids to be determined was filled into a plastic funnel for solids
(diameter of the outlet: 11 mm) with closable outlet which was
mounted in a height of 20 mm above the collecting vessel. The
funnel used was always filled half-full, thereby ensuring that
there was always more sample material provided than necessary for
filling the collecting vessel. After opening the outlet the
respective solids trickled into the collecting vessel until it was
filled up above the upper rim. The supernatant of the respective
solids was removed with a spatula and the filled collecting vessel
was weighed out with a high-resolution balance. The determination
for each form was repeated 10 times and the mean value was
calculated (Table 3).
Results:
[0069] Form III exhibits a higher bulk density compared to the
anhydrate forms known so far as well as compared to the dihydrate,
whereby the difference in bulk density is highly significant
compared to the dihydrate and also to form II (p<0.001, t-test,
unpaired, 2-tailed).
TABLE-US-00003 TABLE 3 Bulk densities [kg/m.sup.3] of forms I-III
and of the dihydrate (mean .+-. standard deviation) Form I Form II
Form III Dihydrate 201.9 .+-. 3.9 108.6 .+-. 3.0 203.5 .+-. 6.7
72.3 .+-. 4.1
Example 2: Maximum Solubility in Water at RT
[0070] The maximum solubility of crystalline form III in water at
RT--until a saturated solution is generated--was determined.
Accordingly, form III with a value of 145 mg/mL is less soluble
than forms I and II (cf. WO2011/107295A1).
[0071] Determination of the maximum solubility of crystalline form
III in water at RT was carried out with UV-Vis spectroscopy in an
Agilent Cary 300 UV-Vis spectrometer. This process is based on a
linear correlation between the concentration of a dissolved solid
and the calculated absorption at a particular wavelength
(Beer-Lambert law).
[0072] A stock solution of 0.502 g of form III in 2 mL H.sub.2O
(demineralized) was produced. For the generating a 3-point
calibration curve three solutions were produced after appropriate
dilution thereof with concentrations of 0.5041 mmol/l, 0.2521
mmol/l and 0.1260 mmol/l, and their respective absorption at 347 nm
was determined. At this wavelength
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salts exhibit an
absorption maximum in the UV spectrum. Further, a supersaturated
solution of 0.531 g of form III in 2 mL H.sub.2O (demineralized)
was produced to determine the maximum concentration. 100 .mu.L of
the solution were 2000-fold diluted and the absorption at 347 nm
was determined as well.
[0073] Accordingly, the calculated value for the maximum solubility
of form III in water at RT was 145 mg/mL (this corresponds to a
maximum concentration of 0.73 mol/l).
Example 3: Slurry Experiments
[0074] In polymorphs of crystalline solids phase transitions occur
depending on the thermodynamic stability of the individual forms.
Herein applies that the thermodynamically less stable (metastable)
form transforms into the thermodynamically more stable form.
Different transformation processes are known. There are solid phase
transitions--where an energy input (temperature, pressure, etc.)
into a phase mixture induces the transition of the
thermodynamically less stable into the more stable form--and
solvent-induced phase transitions--where the dissolution of the
metastable form takes place in favor of crystal nucleation and
crystal growth of the stable form. In this respect so-called slurry
experiments can provide information on the thermodynamic stability
of polymorphs of a solid.
[0075] To compare the stability under the influence of solvents
50:50 (wt %) solid phase mixtures were produced of form III
according to the invention and form I as well as of form III
according to the invention and form II.
[0076] In each case 0.05 g of the respective solid phase mixture
were suspended in 5 mL 2-propanol, methanol or ethanol,
respectively. The mixture of form III and form I was stirred at RT
for 3 days. The mixture of form III and form II was stirred at RT
for 24 h. The suspensions were filtered under vacuum utilizing a
Buchner funnel. The remaining crystalline solid was completely
dried at RT. X-ray powder diffraction patterns of the resulting
crystalline solids were recorded with a Bragg-Brentano
diffractometer (STOE STADI P) provided with a DECTRIS MythenlK
detector using mono-chromatized (Gel111-monochromator) copper
emissions Cu K(.alpha.1) (wave length .lamda.=1.54187 .ANG.).
Results:
[0077] After stirring for 24 hours a significant intensity increase
of reflections showed for the mixture of form II and form III in
the recorded X-ray powder diffractograms with all solvents which
can clearly be assigned to form III (FIG. 6a). Therefore it must be
assumed that form III is the thermodynamically more stable
polymorph at RT in comparison to form II.
[0078] After stirring for 3 days a significant intensity increase
of reflections showed for the mixture of form I and form III in the
recorded X-ray powder diffractograms with all solvents, which can
clearly be assigned to form III (FIG. 6b). According to these
results form III is likewise the thermodynamically more stable
polymorph at RT in comparison to form II.
Biological Efficacy
[0079] The biological efficacy of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt has been
repeatedly proven in the past.
[0080] The comparable biological efficacy of form III compared to
form I and II and the dihydrate could be shown in vitro in
LPS-induced HL60 cells (Example 4).
Example 4--Differentiated HL60 Cells
[0081] For example, it is known from WO2011/107295A1 that both form
I as well as form II are able to reduce the secretion of cytokines,
in particular of TNF alpha and IL-6, both in vitro as well as in
vivo. This could now be confirmed in an in vitro model for form III
as well. Not only the forms already known but also the form III
according to the invention leads to a reduction of the cytokine
secretion in a model with LPS-induced HL60 cells (human
promyelocytic leukemia cells) which were differentiated to
macrophages.
[0082] For the differentiation to macrophages HL60 cells were
treated with phorbol 12-myristate 13-acetate (PMA) in advance.
Subsequently, the cells were pre-stimulated with 1 mmol/l
dihydrate, form I, II or III, respectively, before 100 ng/mL
lipopolysaccharides (LPS) were added for 24 hours. Said amount of
LPS without prior adding of the active ingredient was used as
control (100%). The secretion of TNF alpha and IL-6 was determined
in the cell supernatant using ELISA testing over 3 measurements,
respectively. Table 4 as well as FIGS. 7a and 7b show the
respective mean value m and the standard deviation s (GraphPad
Prism 5).
[0083] The dihydrate of 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt as well as the anhydrate forms form I, II and III all
showed a more or less clearly decreased secretion of TNF alpha and
IL-6 in HL60 cells. Therefore form III has a biological efficacy
comparable to the dihydrate and forms I and II.
TABLE-US-00004 TABLE 4 TNF alpha and IL-6 secretion in
LPS-stimulated HL60 cells TNF-alpha (pg/mL) IL-6 (pg/mL) Form m s m
s Control 30.08 3.56 42.81 2.29 Dihydrate 26.87 0.68 40.93 2.29
Form I 25.28 4.29 41.15 1.10 Form II 22.16 0.90 36.11 3.27 Form III
22.15 4.69 34.86 2.98
[0084] Thus it could be demonstrated in a standard in vitro system
that form III of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium
salt according to the invention has an equivalent or even better
biological efficacy concerning the essential inflammatory markers
TNF alpha and IL-6 when compared with the known forms I and II and
the dihydrate. Hence in therapeutic use an equivalent or better
effect compared to prior art is to be expected.
Production of the Crystalline Form According to the Invention
[0085] In the following the manufacturing of crystalline form III
is described exemplarily.
[0086] Starting material for the synthesis is
5-amino-2,3-dihydrophthalazine-1,4-dione known from prior art,
which for example can be produced according to the following
reaction scheme:
##STR00002##
[0087] Depicted is the synthesis of
5-amino-2,3-dihydrophthalazine-1,4-dione (iii) by reacting
3-nitrophthalic acid (i) which in an alkaline medium can be reduced
via 3-nitrophthalanhydride to
5-amino-2,3-dihydrophthalazine-1,4-dione (ii) with hydrazine or one
of its salts or any other suitable reducing agent, e.g. ammonium
sulfite or triethylene glycol. Suitable production processes for
5-amino-2,3-dihydrophthalazine-1,4-dione can be found in
Williamson, K. L. In: Macroscale and Microscale Organic
Experiments; 2.sup.nd ed.; D. C. Heath: Lexington, Mass., 1994. A
further suitable method for the production of
5-amino-2,3-dihydrophthalazine-1,4-dione which uses a Raney nickel
catalyst can e.g. be found in U.S. Pat. No. 6,489,326 B1.
[0088] A preferred more specific method for a production
independent of the amount of the starting material
5-amino-2,3-dihydrophthalazine-1,4-dione is described in
WO2011/107295A1: Herein 1 equivalent of 3-nitrophthalic acid and
1.1 equivalents of hydrazine hydrate are provided and mixed with
1.5 equivalents of ethylene glycol. In parallel, the temperature is
raised up to 110-200.degree. C. and water is removed by
distillation. When no more water is built the mixture is cooled
down to 100.degree. C. and 6 equivalents water are added. After
cooling the mixture to room temperature and stirring over night the
precipitate is filtered, washed with water and then dried to
constant mass.
[0089] Subsequently, anhydrate form I or II of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt can be
produced by mixing 5-amino-2,3-dihydrophthalazine-1,4-dione in
sodium hydroxide and dropwise adding this solution into a
low-molecular liquid alcohol which lowers the solubility product of
the generated 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt
in such a way that the latter starts to precipitate. The
precipitate generated by precipitation is dried thereafter.
WO2011/107295A1, for example, provides various detailed methods for
the production of anhydrate forms I and II.
[0090] Subject-matter of the present invention are also methods for
the production of anhydrate form III by solving any anhydrate form
of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt (pure form
or mixture) at at least 90.degree. C. while stirring in DMSO
(dimethyl sulfoxide). Stirring is continued until--approximately
after one hour--the solution is completely clear. Thereafter the
solution is stirred further on at constant temperature as possible
(+20.degree. C.) until a suspension is generated. Subsequently, the
solution is--without stirring--further held at constant temperature
(.+-.20.degree. C.) as possible until DMSO is completely
evaporated. The methods are further specified in the following
production examples.
Production Example 1--Embodiment 1
[0091] A possible production of form III comprises the addition of
any anhydrate form (form I, form II, or a mixture of form I and
form II) of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt to
DMSO at a weight ratio of 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt to DMSO from 1 to 300 up to 1 to 30,000; preferred from
1 to 300 up to 1 to 3,000; particularly preferred from 1 to 300 up
to 1 to 350. The mixture is stirred until complete
dissolution--i.e. until apparently there are no more
turbidities--at a temperature from 90.degree. C. to 189.degree. C.,
preferably from 100.degree. C. to 170.degree. C., particularly
preferably from 120.degree. C. to 150.degree. C., whereas
189.degree. C. corresponds to the boiling point of DMSO.
[0092] The solution is further stirred at 90.degree. C. to
189.degree. C., preferably at 100.degree. C. to 170.degree. C.,
particularly preferably at 120.degree. C. to 150.degree. C. until a
suspension is generated, which is characterized by the recurrence
of turbidities, wherein preferably the temperature range of the
previous dissolution step is maintained, preferably within a range
of 10.degree. C., particularly preferably within .+-.1.degree.
C.
[0093] The suspension is dried--without stirring--at 90.degree. C.
to 189.degree. C., preferably at 100.degree. C. to 170.degree. C.,
particularly preferably at 120.degree. C. to 150.degree. C., until
a finely powdered solid is generated, wherein preferably the
temperature range of the previous dissolution step is further
maintained, preferably within a range of .+-.10.degree. C.,
particularly preferably within .+-.1.degree. C.
Production Example 1--Embodiment 2
[0094] A preferred embodiment for the production of form III
comprises the pre-heating of DMSO to a temperature of 90.degree. C.
to 189.degree. C., preferably 100.degree. C. to 170.degree. C.,
particularly preferably 120.degree. C. to 150.degree. C., before
any anhydrate form (form I, form II, or a mixture of form I and
form II) of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt is
added to DMSO at a weight ratio of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt to DMSO from 1
to 300 up to 1 to 30,000; preferably from 1 to 300 up to 1 to
3,000; particularly preferably from 1 to 300 up to 1 to 350,
whereas 189.degree. C. corresponds to the boiling point of
DMSO.
[0095] The mixture is stirred until complete dissolution--i.e.
until apparently there are no more turbidities--at a temperature
from 90.degree. C. to 189.degree. C., preferably from 100.degree.
C. to 170.degree. C., particularly preferably from 120.degree. C.
to 150.degree. C.
[0096] The solution is stirred at 90.degree. C. to 189.degree. C.,
preferably at 100.degree. C. to 170.degree. C., particularly
preferably at 120.degree. C. to 150.degree. C. until a suspension
is generated, which is characterized by the recurrence of
turbidities wherein the temperature range of the previous
dissolution step is maintained, preferably within a range of
+10.degree. C., particularly preferably within 1.degree. C.
[0097] The suspension is dried--without stirring--at 90.degree. C.
to 189.degree. C., preferably at 100.degree. C. to 170.degree. C.,
particularly preferably at 120.degree. C. to 150.degree. C., until
a finely powdered solid is generated, wherein preferably the
temperature range of the previous dissolution step is further
maintained, preferably within a range of .+-.10.degree. C.,
particularly preferably within .+-.1.degree. C.
Production Example 1--Embodiment 3
[0098] In a particularly preferred embodiment of the production
example crystalline form III can be produced as follows:
[0099] 100 mL DMSO are heated in a beaker large enough, preferably
in a 200 mL beaker, up to at least 90.degree. C., preferably up to
at least 100.degree. C., particularly preferably up to at least
120.degree. C.
[0100] Adding 300 mg 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt anhydrate to DMSO while stirring continuously and
maintaining the selected temperature, preferably within a range of
.+-.10.degree. C., particularly preferably within .+-.1.degree.
C.
[0101] Stirring the 5-amino-2,3-dihydrophthalazine-1,4-dione sodium
salt-DMSO mixture while further maintaining the temperature,
preferably within a range of .+-.10.degree. C., particularly
preferably within .+-.1.degree. C., until complete dissolution,
preferably for less than 24 hours, particularly preferably for less
than 12 hours.
[0102] Stirring the 5-amino-2,3-dihydrophthalazine-1,4-dione sodium
salt solution in DMSO while further maintaining the temperature,
preferably within a range of .+-.10.degree. C., particularly
preferably within .+-.1.degree. C., until a suspension is
generated, preferably for less than 20 days, particularly
preferably for less than 10 days.
[0103] Drying the suspension while maintaining the temperature,
preferably within a range of +10.degree. C., particularly
preferably within .+-.1.degree. C., however without stirring, until
a finely powdered solid is generated, preferably for less than 10
days, particularly preferably for less than 5 days.
[0104] Weighing the substance and determining the yield, amounting
preferably to more than 200 mg, particularly preferably to almost
300 mg.
Production Example 2--Embodiment 1
[0105] A possible production of form III comprises the addition of
any anhydrate form of 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt (form I, form II, or a mixture of form I and form II)
to DMSO at a ratio of 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt to DMSO from 1 to 300 up to 1 to 30,000; preferably
from 1 to 300 up to 1 to 3,000; particularly preferably from 1 to
300 up to 1 to 350. The mixture is stirred until complete
dissolution--i.e. until apparently there are no more
turbidities--at a temperature from 90.degree. C. to 189.degree. C.,
preferably from 100.degree. C. to 170.degree. C., particularly
preferably from 120.degree. C. to 150.degree. C.
[0106] The solution is further stirred--while applying a vacuum
within the range of 5.times.10.sup.-3-20.times.10.sup.-3 mbar,
preferably 5.times.10.sup.-3-10.times.10.sup.-3 mbar, particularly
preferably 8.times.10.sup.-3-10.times.10.sup.-3 mbar--at 70.degree.
C. to 189.degree. C., preferably at 90.degree. C. to 170.degree.
C., particularly preferably at 120.degree. C. to 150.degree. C.
until a suspension is generated, which is characterized by the
recurrence of turbidities wherein the temperature range of the
previous dissolution step is maintained, preferably within a range
of .+-.20.degree. C., particularly preferably within .+-.5.degree.
C.
[0107] The suspension is dried under vacuum within the range of
5.times.10.sup.-3-20.times.10.sup.-3 mbar, preferably
5.times.10.sup.-3-10.times.10.sup.-3 mbar, particularly preferably
8.times.10.sup.3-10.times.10.sup.-3 mbar, at 70.degree. C. to
189.degree. C., preferably at 90.degree. C. to 170.degree. C.,
particularly preferably at 120.degree. C. to 150.degree. C., until
a solid is generated, wherein the temperature range of the
dissolution step is further maintained, preferably within a range
of .+-.20.degree. C., particularly preferably within .+-.5.degree.
C.
[0108] The solid is suspended with 2-propanol and filtered under
vacuum utilizing a Buchner funnel. It is rinsed twice with
2-propanol. Subsequently, the finely powdered solid is dried at
50.degree. C. in a drying cabinet to constant mass.
[0109] Production example 2 is in particular suitable when larger
amounts of starting material are used, e.g. for the production of
industrial scale batches.
Production Example 3 Crystalline Form III
[0110] To increase the yield of the synthesis a further possible
production of form III comprises the addition of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt to a
DMSO-H.sub.2O mixture (99/1 vol % to 1/99 vol %). Due to the
miscibility of DMSO and H.sub.2O and the higher maximum solubility
of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt in H.sub.2O
compared to DMSO a higher proportion of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt can be
dissolved. Further synthesis is preferentially carried out
analogous to the previous production examples.
[0111] The solubility of 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt with regard to the variable proportion of water in the
DMSO-H.sub.2O mixture is displayed in FIG. 8. With an increasing
proportion of water in the mixture the maximum solubility of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt increases
continuously. The higher H.sub.2O volume fractions in the
DMSO-H.sub.2O mixture are only important for the initial
dissolution step. During the subsequent heating step (with regard
to a reasonable yield of form III in a preferred temperature range
>100.degree. C., see production example 1--embodiments 1 and 2)
the H.sub.2O proportion evaporates from the solvent mixture.
Without a DMSO proportion with a weight ratio of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt to DMSO of at
least 1 to 300 (see production example 1--embodiment 1) no
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt form III is
built during the final drying step--or at least no phase-pure form
III. The optimum mixing ratio of DMSO to H.sub.2O for the initial
dissolution step thus results from the respective industrial
production conditions. Generally preferred is a proportion of water
in the DMSO-H.sub.2O mixture of 30% to 80%, further preferred of
40% to 70% and mostly preferred of 50% to 60%.
[0112] Also production example 3 is suitable when larger amounts of
starting material are used and thus for the production of
industrial scale batches.
[0113] Due to the first step of the production example shown
before, namely the selection of a suitable DMSO-H.sub.2O ratio, the
maximum solubility of 5-amino-2,3-dihydrophthalazine-1,4-dione
sodium salt can be set depending on the intended use. This option
is not available in production methods for
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salts described so
far. Thus this optional production step for form III itself
represents already an advantage over the state of the art.
[0114] Possible application examples comprise industrial production
of active ingredients and the production of topical applications.
For the industrial production of active ingredients following
validated GMP requirements the setting of the maximum solubility
can be a substantial advantage with regard to the accuracy of the
quantity and the phase purity of the desired crystal form. For the
production of topical applications this can be an advantage, as
herein a maximum solubility in water often is not considered as
desirable.
Production Example 4 Crystalline Form II
[0115] A possible production of form II comprises initially the
production of a pure form of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt dihydrate, for
instance according to U.S. Pat. No. 6,489,326 B1. Alternatively,
any form for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt
can be dissolved in water while stirring until apparently there are
no more turbidities. Herein the ratio of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt to water is 1
to 2-50, preferred 1 to 5-50, particularly preferred 1 to 10.
Subsequently, 2-propanol is added to the solution and the generated
suspension is further stirred. Herein the ratio of the already
present solution to propanol is 1 to 2-50, preferred 1 to 4-20,
particularly preferred 1 to 8-10. Stirring time is at least 1 hour,
preferred at least 2 h, particularly preferred at least 4 h.
Subsequently, the suspension is filtered, preferably under
vacuum.
[0116] The remaining crystalline solid (dihydrate) is then dried at
a temperature of 60.degree. C. to 100.degree. C., preferably at
60.degree. C. to 90.degree. C., particularly preferably at
60.degree. C. to 75.degree. C., mostly preferably at 60.degree. C.
to 65.degree. C. in a drying cabinet to constant mass.
[0117] According to the invention the modifications concerning the
methods of production as shown in the production examples and
embodiments for form III shall be freely combinable among each
other, as long as there are no logical constraints.
Medical Use:
[0118] On the basis of the previously described physicochemical and
biological characteristics according to the invention form III is
suitable--analogous to forms I and II--as active ingredient for use
in medicine, in particular for use as anti-inflammatory and
immunoregulatory agent, e.g. for the treatment of conditions with
excessive immune responses and for the treatment of conditions with
an immunodeficient background.
[0119] Conditions with excessive immune responses are for instance
graft rejections after transplantations; active autoimmune diseases
respectively diseases with autoimmune components; in particular
active rheumatoid arthritis, relapsing multiple sclerosis, lupoid
hepatitis, polyarteriitis nodosa, Crohn's disease, colitis
ulcerosa, dermatomyositis, Behcet's disease, uveitis in patients
with Behcet's disease, idiopathic thrombocytopenic purpura,
myasthenia gravis, Lambert-Eaton myasthenic syndrome, polymyositis,
psoriasis, psoriasis arthritis, Bekhterev's disease, paroxysmal
nocturnal hemoglobinuria, ankylosing spondylitis, autoimmune
thyroidites (as e.g. Hashimoto thyroiditis, Ord's thyroiditis or
Grave's disease), lupus erythematodes, vitiligo, autoimmune
encephalomyelitis, idiopathic optic neuritis, sympathetic
ophthalmia, anterior uveitis, retinal degeneration, peripheral
ulcerative keratitis, bullous pemphigoid, chronic urticaria,
dermatitis herpetiformis Duhring, epidermolysis bullosa acquisita,
alopecia areata, autoimmune enteropathy, autoimmune polyendocrine
syndromes (as e.g. APECED (autoimmune polyendocrinopathy
candidiasis ectodermal dystrophy), Schmidt's syndrome and XPID
(X-linked polyendocrinopathy immunodeficiency and diarrhea
syndrome)), chronic gastritis, dermatomyositis, diabetes mellitus
type 1, diabetes mellitus type 2, Graves' ophthalmopathy,
glomerulonephritis, Goodpasture's syndrome, granulomatosis with
polyangiitis, Guillain-Barre syndrome, lichen sclerosus, lichen
mucosae, IgA pemphigus, microscopic polyangiitis, chronic fatigue
syndrome, narcolepsy, PANS (pediatric autoimmune neuropsychiatric
syndrome) (as e.g. PANDAS (pediatric autoimmune neuropsychiatric
disorders associated with streptococcal infections)), pemphigus
foliaceus, pemphigus seborrhoicus, pemphigus vulgaris,
polychondritis, polymyalgia rheumatica, rheumatic fever, SAPHO
syndrome (synovitis, acne, pustulosis, hyperostosis, osteitis),
sarcoidosis, Sjogren's syndrome, scleroderma, stiff-person
syndrome, Hennoch-Schonlein purpura, celiac disease, acute
disseminated encephalomyelitis, antiphospholipid syndrome,
autoimmune cardiomyopathy, autoimmune hemolytic anemia, autoimmune
inner ear disease, autoimmune lymphoproliferative syndrome,
autoimmune pancreatitis, autoimmune polyendocrine syndrome,
autoimmune progesterone dermatitis, Chagas' disease, chronic
inflammatory demyelinating polyneuropathy, chronic recurrent
multifocal osteomyelitis, COPD (chronic obstructive pulmonary
disease), Churg-Strauss syndrome, cold agglutinin disease, adiposis
dolorosa, endometriosis, eosinophilic fasciitis, Hashimoto's
encephalopathy, acne inversa, interstitial cystitis, Kawasaki
disease, Sharp's syndrome, neuromyotonia, opsoclonus myoclonus
syndrome, primary biliary cirrhosis, Raynaud's syndrome, restless
legs syndrome, transverse myelitis and vasculitis, aplastic anemia,
pemphigus, pemphigoid, endogenous uveitis, nephrotic syndrome and
atopic dermatitis; as well as septic conditions e.g. induced by
infections with Gram-negative or Gram-positive bacteria (e.g. MRSA
(methicillin-resistant Staphylococcus aureus)) or mycotic pathogens
and systemic inflammatory response syndrome (SIRS) induced by other
(e.g. immunologic or chemical) factors.
[0120] Conditions with immunodeficient background are for instance
frequent flues, relapsing respiratory tract infections, relapsing
infections of the efferent urinary tract, fatigue, weakness,
absent-mindedness of unknown genesis, reconvalescence, chronic
viral infections (in particular human immunodeficiency viruses
(e.g. HIV-1, HIV-2), hepatitis B, hepatitis C, encephalitis, herpes
zoster, herpes simplex, infections of the inner ear, varicella,
measles, cytomegaly, Epstein-Barr, adenoviruses, human papilloma
viruses and parvoviruses, such as amdoparvoviruses,
bocaparvoviruses, dependoparvoviruses, erytrhroparvoviruses and
parvovirus spec.), different oncologic diseases (in particular
hairy cell leukemia, myeloid leukemia, multiple myeloma, follicular
lymphoma, Kaposi's sarcoma, cutaneous T-cell lymphoma,
nasopharyngeal carcinoma, carcinoid, renal carcinoma, bladder
carcinoma, basal cell carcinomas, metastasizing carcinomas and
malignant melanoma), septic granulomatosis, neutropenia, genital
warts, keratoses, autoimmune diseases (in particular non-active
stages such as relapsing multiple sclerosis between relapses),
radiogenic colitis, diverticulitis, allergies (in particular hay
fever, polymorphous light eruption, eczema, neurodermatitis),
enteritis, colitis, as well as before, during and after
chemotherapies and radiation therapies.
[0121] Summing up it can be said the form according to the
invention is in principle suitable for the treatment of all
inflammatory diseases that are associated with a more or less
significant increase of pro-inflammatory cytokines, in particular
with the increase of IL-6 and TNF alpha. This is--in addition to
those already mentioned--also the case for example within the scope
of wound healing, e.g. after surgical interventions, for immune
processes out of control (as e.g. Keratitis sicca) or for acute and
chronic inflammations of unknown etiology (as e.g. tendovaginitis
or osteoarthritis).
Pharmaceutical Preparations and Routes of Administration
[0122] Pharmaceutical formulations of the active ingredient
according to the invention, alone or in combination with adjuvants
and standard therapies, can be formulated as liquid and solid and
can be administered by any pharmaceutically acceptable way, above
all, but nor limiting intravenously, intramuscularly, topically
(e.g. conjunctivally as eye drops or transdermally as an ointment
or substance-eluting wound pad), parenterally (incl.
subcutaneously, intramuscularly, intravenously, intraarterially or
intradermally), vaginally, rectally, nasally, or orally, including
sublingually and buccally, as well as in form of drug-eluting
implants.
[0123] Liquid forms can be: e.g. solutions (e.g. for injections and
infusions), juices, syrups, drops, teas, suspensions in aqueous or
non-aqueous liquids, emulsions, in particular oil-in-water lotions
or water-in-oil liquid lotions and sprays.
[0124] Solid forms, in particular for oral administration, can be:
Tablets, dragees, capsules, pills, fine powders, powders,
granulates, or other forms known as suitable to a person skilled in
the art, e.g. suppositories.
[0125] For topical administrations of the polymorph according to
the invention creams, emulsions, lotions, gels, pastes, fine
powders, ointments and suspensions are suitable.
[0126] Tablets are for example formulated by producing, granulating
or dry-pressing a powder mixture, adding a lubricant and a
disintegrant and pressing the mixture to a tablet.
[0127] Powders are produced by grinding the compound to a suitably
fine size and or mixing it with a similarly ground pharmaceutical
carrier such as edible carbohydrate such as starch or mannitol. A
flavor, preservative, dispersant and colorant can be likewise
present.
[0128] A granulate is produced by mixing the compound ground for
the powder mixture in a suitable manner with a diluent or a base as
described before, and, if appropriate, with a binder such as
carboxymethyl cellulose, an alginate, gelatin or polyvinyl
pyrrolidone, a dissolution retardant such as paraffin, an
absorption accelerator such as a quaternary salt and/or an
absorbent such as bentonite, kaolin or dicalcium phosphate. The
powder mixture can be granulated by wetting it with a binder such
as syrup, starch paste, mucilage (e.g. acacia) or solutions of
cellulose or polymer materials and pressing it through a sieve.
[0129] Alternatively, a powder mixture can be processed by a
tableting machine, wherein unevenly formed clumps are generated
that can be broken up to granulates. The granulates can be
lubricated by adding stearic acid, its salts (stearates), talc or
mineral oil in order to avoid a baking at the tableting mold. The
lubricated mixture is then pressed to tablets. The compounds
according to the invention can also be combined with a free-flowing
inert carrier and then be pressed to tablets directly without
performing the granulation and dry-press steps.
[0130] Capsules are produced by producing a powder mixture as
described before and filling it into cast gelatin containers.
Glidants and lubricants such as highly dispersible silica, talc,
magnesium stearate, calcium stearate or polyethylene glycol as a
solid can be added to the powder mixture before filling. A
disintegrant or solution enhancer such as agar agar, calcium
carbonate or sodium carbonate can be likewise added for improving
the availability of the medication after intake of the capsule.
[0131] For producing a dosage form as a suppository with the
compounds according to the invention waxes with a low melting point
as well as a mixture of fatty acid glycerides such as cocoa butter
are melted first and then the active ingredient according to the
invention is dispersed therein homogeneously under stirring or
other mixing methods. The molten homogeneous mixture is then
transferred to a suitable mold, let cool down and thus
solidified.
[0132] The anhydrate form according to the invention can be mixed
with all carriers known in the art, for solid dosage forms e.g.
with vegetable and animals fats, waxes, paraffins, starch,
tragacanth, cellulose derivatives, polyethylene glycol, silicones,
bentonites, silica, talc, zinc oxide or mixtures of the
aforementioned substances. Thus for an oral administration in form
of a tablet or capsule the active ingredient component can be
combined e.g. with an oral, non-toxic and pharmaceutically
acceptable inert carrier such as ethanol, glycerin, water and the
like.
[0133] For liquid dosage forms and emulsions suitable carriers are
for example solvents, solubilizing agents, emulsifiers such as
water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl
alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol,
cotton seed oil, peanut oil, olive oil, castor oil, sesame oil,
glycerol fatty acid esters, polyethyl glycols, fatty acid esters of
sorbitan, or mixtures of the aforementioned substances.
[0134] Suspensions according to the invention may use carriers
known in the art such as diluents (e.g. water, ethanol or propylene
glycol), ethoxylized isostearyl alcohols, polyoxyethylene and
polyoxyethylene sorbitan esters, microcrystalline cellulose,
bentonites, agar agar, tragacanth or mixtures of the aforementioned
substances.
[0135] Excipients may also influence for example the distribution
of an active ingredient in different tissues and organs or modify
the effect duration or effect velocity of dosage forms, e.g. by
accelerating the absorption (e.g. by dimethyl sulfoxide, nicotinic
acid, hyaluronidase, taurine), or by retarding the onset of effect,
e.g. in depot dosage forms e.g. by polylactide-co-glycolide
(PLGA).
[0136] In topical application forms the term "penetration
enhancers" is used. This comprises e.g. isopropyl myristate, oleic
acid, sodium lauryl sulfate and 1,2-propanediol.
[0137] Liquid dosage forms comprise solutions, suspensions and
emulsions. Examples are isotonic saline solution, Ringer solutions,
Ringer lactate solutions, Ringer acetate solutions, water and
water/propylene glycol solutions for parenteral injections or the
addition of sweeteners and opacifiers for oral solutions,
suspensions and emulsions. Liquid dosage forms can also comprise
solutions for intranasal administration and eye drops.
[0138] Moreover, buffer solutions can be components of
pharmaceutical compositions. Preferred buffer systems may be
selected from the group comprising formate, lactate, benzoic acid,
oxalate, fumarate, aniline, acetate buffer, citrate buffer,
glutamate buffer, phosphate buffer, succinate, pyridine, phthalate,
histidine, MES (2-(N-morpholino) ethanesulfonic acid), maleic acid,
cacodylate (dimethyl arsenate), carbonic acid, ADA
(N-(2-acetamido)imino diacetic acid), PIPES
(4-piperazine-bis-ethanesulfonic acid), BIS-TRIS propane
(1,3-bis[tris(hydroxymethyl)methylaminol] propane), ethylene
diamine, ACES (2-[(amino-2-oxoethyl)amino]ethanesulfonic acid),
imidazol, MOPS (3-(N-morphino)-propanesulfonic acid, diethyl
malonic acid, TES (2-[tris(hydroxymethyl)methyl]aminoethanesulfonic
acid, and HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid), as well as other buffers with a pKa between 3.8 and 7.7.
[0139] Preferred are carbonic acid buffers such as acetate buffer
and dicarboxylic acid buffers such as fumarate, tartrate and
phthalate as well as tricarboxylic acid buffers such as citrate. A
further group of preferred buffers are inorganic buffers such as
sulfate, borate, carbonate, oxalate, calcium hydroxide and
phosphate buffers. Yet another group of preferred buffers are
nitrogen-containing buffers such as imidazol, diethylene diamine
and piperazine. Furthermore preferred are sulfonic acid buffers
such as TES, HEPES, ACES, PIPES, TAPS
([(2-hydroxy-1,1-bis-(hydroxymethyl)ethyl)amino]-1-propanesulfonic
acid), EEPS (4-(2-hydroxyethyl)piperazine-1-propanesulfonic acid),
MOPS (4-morpholino-propanesulfonic acid) and BES
(N,N-bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid). Another
group of preferred buffers are glycine, glycyl-glycine,
glycyl-glycyl-glycine, N,N-bis-(2-hydroxyethyl)glycine and
N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine (tricine).
Preferred are also amino acid buffers such as glycine, alanine,
valine, leucine, isoleucine, serine, threonine, phenylalanine,
tyrosine, tryptophan, lysine, arginine, histidine, aspartate,
glutamate, asparagine, glutamine, cysteine, methionine, proline,
4-hydroxy proline, N,N,N-trimethyllysine, 3-methyl histidine,
5-hydroxy-lysine, o-phosphoserine, gamma-carboxyglutamate,
[epsilon]-N-acetyl lysine, [omega]-N-methyl arginine, citrulline,
ornithine and their derivatives.
[0140] Pharmaceutical excipients for use in the respectively
desired application form can be for example: Sodium citrate,
calcium phosphate, calcium carbonate together with a suitable
tablet disintegrant, e.g. for oral administration.
[0141] To the disintegrants belong, without being limiting, starch,
cold water-soluble starches such as carboxymethyl starch, cellulose
derivatives such as methyl cellulose and sodium carboxymethyl
cellulose, microcrystalline cellulose and cross-linked
microcrystalline celluloses such as croscarmellose sodium, natural
and synthetic gums such as guar, agar, karaya (Indian tragacanth),
locust bean gum, tragacanth, clays such as bentonite, xanthan gum,
alginates such as alginic acid and sodium alginate, foaming
compositions a.o. Moisture expansion is supported by for example
starch, cellulose derivatives, alginates, polysaccharides,
dextrans, cross-linked polyvinyl pyrrolidone. The amount of the
disintegrant in the composition may vary between 1 and 40% per
weight, preferred between 3 and 20% per weight, most preferred
between 5 and 10% per weight.
[0142] Substances that can produce gas through a reaction with
water (sodium hydrogen carbonate, citric and tartric acid) or
substances improving the wetting of crystallites as a hydrophilizer
and thus support the dissolution e.g. in water (solubilizers, e.g.
polyethylene glycol sorbitan fatty acid esters).
[0143] Excipients are also substances that can be used as binders
such as starch (e.g. from wheat, corn, rice or potato), gelatin,
sugars such as glucose, sucrose or beta-lactose, sweeteners (e.g.
from corn), natural and synthetic gum such as acacia, tragacanth or
ammonium calcium alginate, sodium alginate, polyethylene glycol,
polyvinyl pyrrolidone, magnesium aluminium silicate, waxes,
cellulose derivatives such as carboxymethyl cellulose, sodium
carboxymethyl cellulose, hydroxypropyl carboxymethyl cellulose, or
thinners such as sugars (e.g. mannitol).
[0144] To the excipients belong for example also lubricants,
glidants, flavors or aromas, antioxidants, colorants, preservatives
and surface-active substances such as sodium lauryl sulfate or
polysorbate 80.
[0145] In tablet production, lubricants are usually added shortly
before pressing, as they should be present on the surface of the
granules and between them and the parts of the press mold. The
amount of the lubricant in the composition may vary between 0.05
and 15% per weight, preferred between 0.2 and 5% per weight, more
preferred between 0.3 and 3% per weight, most preferred between 0.3
and 1.5% per weight.
[0146] To the lubricants used in these dosage forms belong sodium
oleate, metal stearates such as sodium stearate, calcium stearate,
potassium stearate and magnesium stearate, stearic acid, sodium
benzoate, sodium acetate, sodium chloride, boric acid, waxes having
a high melting point, polyethylene glycol a.o.
[0147] Suitable glidants comprise silicon dioxide, magnesium
stearate, sodium stearate, starch and talcum. The amount of the
glidant in the composition may vary between 0.01 and 10% per
weight, preferred between 0.1 and 7% per weight, more preferred
between 0.2 and 5% per weight, most preferred between 0.5 and 2%
per weight.
[0148] Suitable examples for flavors or aromas are essential oils,
vitamins and galenic excipients selected from sugars, sugar
substitutes, nutritional sweeteners, acidifiers, solubilizers such
as water, glycol, glycerin, thickening agents, sweeteners,
colorants or preservatives or combinations thereof, also depending
from the galenic dosage form.
[0149] Suitable aromas and flavors comprise above all essential
oils that can be used as aromas, respectively also as flavors. In
general, this term refers to volatile extracts from plants or parts
of plants with the respective characteristic smell that can be
extracted from plants or parts of plants by steam distillation.
[0150] As examples can be mentioned: Essential oils, respectively
aromatic substances from sage, cloves, chamomile, anise, star
anise, thyme, tea tree, peppermint, mint (menthol, cineol),
eucalyptus, mango, figs, lavender, chamomile blossoms, pine
needles, cypress, oranges, rosewood, plum, currant, cherry, birch
leaves, cinnamon, limes, oranges, grapefruit, tangerine, juniper,
valerian, lemon balm, lemon grass, palmarosa, cranberry,
pomegranate, rosemary, ginger, pineapple, guava, echinacea, ivy
leaves, blueberry, kaki, melons etc. or mixtures thereof, such as
mixtures of menthol, peppermint and star anise oil or menthol and
cherry flavor.
[0151] These aromatic or flavoring substances can be included in
the range of 0.0001 to 10% per weight (particularly in a
composition), preferred 0.001 to 6% per weight, more preferred
0.001 to 4% per weight, most preferred 0.01 to 1% per weight, with
regard to the total composition. Application- or single
case-related it may be advantageous to use differing
quantities.
[0152] The addition of antioxidants is particularly preferable in
topical dosage forms. Suitable examples for antioxidants include
sodium metabisulfite, alpha-tocopherol, ascorbic acid, maleic acid,
sodium ascorbate, ascorbyl palmitate, butylated hydroxyanisol,
butylated hydroxytoluol, fumaric acid or propyl gallate. Preferred
antioxidant is sodium metabisulfite.
[0153] Colorants are can be for example food colorants. They can be
also adsorbed on a suitable adsorption means such as clay or
aluminium oxide. The amount of the colorants may vary between 0.01
and 10% per weight of the composition, preferred between 0.05 and
6% per weight, more preferred between 0.1 and 4% per weight, most
preferred between 0.1 and 1% per weight.
[0154] Suitable colorants are for example curcumin, riboflavin,
riboflavin-5'-phosphate, tartrazine, alkanin, quinolione yellow WS,
Fast Yellow AB, riboflavin-5'-sodium phosphate, yellow 2G, Sunset
yellow FCF, orange GGN, carminic acid, citrus red 2, carmoisine,
amaranth, cochineal, Ponceau 4R, Ponceau SX, Ponceau 6R,
erythrosine, red 2G, Allura red AC, Indathrene blue RS, Patent blue
V, indigo carmine, Brilliant blue FCF, chlorophylls and
chlorophyllins, copper complexes of chlorophylls and
chlorophyllins, Green S, Fast Green FCF, Plain caramel, Caustic
sulphite caramel, ammonia caramel, sulphite ammonia caramel, Black
PN, Carbon black, vegetable carbon, Brown FK, Brown HT,
alpha-carotene, beta-carotene, gamma-carotene, annatto, bixin,
norbixin, paprika oleoresin, capsanthin, capsorubin, lycopene,
beta-apo-8'-carotenal, ethyl ester of beta-apo-8'-carotenic acid,
flavoxanthin, lutein, cryptoxanthin, rubixanthin, violaxanthin,
rhodoxanthin, canthaxanthin, zeaxanthin, citranaxanthin,
astaxanthin, betanin, anthocyanins, saffron, calcium carbonate,
titanium dioxide, iron oxides, iron hydroxides, aluminium, silver,
gold, pigment rubine, tannin, orcein, ferrous gluconate, and
ferrous lactate.
[0155] Preservatives for liquid dosage forms can be used on demand.
They may be selected from potassium sorbate, methyl ethyl paraben,
sodium benzoate and similar substances or mixtures known to a
person skilled in the art for this purpose.
[0156] Typical examples for preservatives suitable for topical
applications are benzyl benzoate, benzoic acid, benzyl alcohol,
benzalkonium chloride, N-cetyl-N,N,-trimethylammonium bromide
(Cetrimid, Merck), chlorhexidine, chlorbutanol, imidurea, parabens
such as methyl-, ethyl-, propyl- or butylparaben, sodium
methylparaben, sodium propylparaben, potassium sorbate, sodium
benzoate, sodium propionate, phenol, phenoxyethanol, phenylethyl
alcohol, phenyl mercuriacetate, phenyl mercuriborate,
phenylmercurinitrate, sorbic acid or thiomersal (sodium
methylmercurithiosalicylate). Preferred are methylparaben,
propylparaben as well as sodium methylparaben and sodium
propylparaben.
[0157] In topical applications are used surface-active solubilizing
agents (solubilizers) such as diethylene glycol monoethyl ester,
polyethyl propylene glycol co-polymers, cyclodextrins, glyceryl
monostearates such as Solutol HS 15 (Macrogol-15-hydroxystearate
from BASF, PEG 660-15 hydroxystearates), sorbitan esters,
polyoxyethylene sorbitanic acid esters, polyvinyl alcohol, sodium
dodecyl sulfate, (anionic) glyceryl monooleates etc.
[0158] Suitable emulsifiers are for example the following anionic
and non-ionic emulsifiers: Anionic emulsifier waxes, cetyl alcohol,
cetylstearyl alcohol, stearic acid, oleic acid, polyoxyethylene
polyoxypropylene block polymers, addition products of 2 to 60 mol
ethylene oxide to castor oil and/or hardened castor oil, wool wax
oil (lanolin), sorbitan esters, polyoxyethylene alkyl esters,
polyoxyethylene sorbitan fatty acid esters or polyvinyl alcohol.
Preferred are glycerin monooleate, stearic acid and phospholipids
such as lecithin.
[0159] Suitable triglycerides are for example medium-chain and high
molecular triglycerides. Medium-chain triglycerides are glycerin
esters of fatty acids with only 6-12 carbon atoms such as
caprylic/capric acid triglyceride. High molecular triglycerides are
glycerin fatty acid esters with long-chained fatty acids. They are
for example, triglyceride mixtures produced from several naturally
occurring fats. Preferred are medium-chain triglycerides, in
particular caprylic/capric acid triglyceride.
[0160] Suitable pH-regulators for topical dosage forms are e.g.
sodium hydroxide, hydrochloric acid, buffer substances such as
sodium dihydrogen phosphate or disodium hydrogenphosphate.
[0161] Cream preparations may also contain other excipients and
additives, such as fatiquors, solvents, consistency enhancers or
hydrotropes for improving the flow characteristics. Herein single
as well as several substances from the same group of additives or
excipients may be present in the mixture.
[0162] Suitable fatiquors are e.g. oleic acid decylester, hydrated
castor oil, light mineral oil, mineral oil, polyethylene glycol,
sodium laurylsulfate.
[0163] Suitable solvents are corn oil, cottonseed oil, peanut oil,
sesame oil, soybean oil, ethyl oleate, glycerin, isopropyl
myristate, isopropyl palmitate, polyethylene glycol or
polypropylene glycol.
[0164] Suitable consistency enhancers are e.g. cetyl alcohol, cetyl
ester wax, hydrated castor oil, microcrystalline waxes, non-ionic
emulsifier waxes, beeswax, paraffin or stearylic alcohol.
[0165] Suitable hydrotropes are alcohols such as ethanol, isopropyl
alcohol or polyols such as glycerin.
Application Examples
[0166] Possible applications are for example, without being
limiting, the following:
[0167] Parenteral applications are for example suitable for acute
and peracute conditions with hospitalization such as septic
conditions, or in the course of planned surgical interventions.
Suitable active ingredient dosages of Form III according to the
invention range from 1 .mu.g to 100 mg/kg body weight, preferred
from 50 .mu.g to 10 mg/kg body weight, particularly preferred from
100 .mu.g to 5 mg/kg body weight. It can be administered once or
twice daily or via permanent infusion, wherein the total daily dose
preferably is max. 100 mg/kg body weight, particularly preferred
max. 50 mg/kg body weight. For surgical interventions it is
recommended to start the dosing at least 12 h, preferred 24 h,
particularly preferred at least 48 h before the actual
intervention. The duration of the treatment depends on the
patient's condition and the nature of the disease. The treatment
should be continued at least to absence of symptoms, preferred for
at least 2 days more after absence of symptoms, particularly
preferred at least 5 days more after absence of symptoms.
[0168] Peroral applications such as tablets or capsules are for
example suitable for acute, subacute, chronic or relapsing
conditions such as rheumatoid arthritis. Suitable active ingredient
dosages for Form III according to the invention range from 1 .mu.g
to 100 mg/kg body weight, preferred from 50 .mu.g to 10 mg/kg body
weight, particularly preferred from 100 .mu.g to 5 mg/kg body
weight. The intake may be once or twice daily, wherein the total
daily dose preferably is max. 100 mg/kg body weight, particularly
preferred max. 50 mg/kg body weight. The interval between two
applications should be preferably min. one hour, particularly
preferred min. 2 hours. The duration of the treatment depends on
the patient's condition and the nature of the disease. The
treatment should be continued at least to absence of symptoms,
preferred for at least 6 days more after absence of symptoms,
particularly preferred at least 14 days more after absence of
symptoms.
[0169] Topical applications such as eye drops or ointments are for
example suitable in form of eye drops for the treatment of
inflammatory diseases of the eye, and for example in form of an
ointment or cream for the treatment of wounds or inflammatory skin
diseases. In the pharmaceutical composition suitable percentages of
the active ingredient for Form III according to the invention range
from 0.05 to 20%, preferred from 0.1 to 10%, particularly preferred
from 0.2 to 5%. The application may be once or twice daily, wherein
the interval between two applications should be preferably min. one
hour, particularly preferred min. 2 hours. The duration of the
treatment depends on the patient's condition and the nature of the
disease. The treatment should be continued at least to absence of
symptoms, preferred for at least 3 days more after absence of
symptoms, particularly preferred at least 10 days more after
absence of symptoms.
[0170] Inventive crystalline Form III of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt can also be
used in combination with at least one further known active
ingredient and/or standard therapy.
[0171] These active ingredients for combinations can be selected
from the group comprising steroidal and non-steroidal
anti-inflammatory agents, immunomodulators, immunosuppressive
agents, antibiotics, anti-infective agents, antiviral agents,
antimycotics, analgesics, local anesthetics, anticoagulants,
thrombocyte aggregation inhibitors, muscle relaxants, tonic agents
and anabolic agents. Such a combination of active ingredients can
be used for prophylactic and/or therapeutic purposes in a person in
need of such an administration.
[0172] Suitable examples for steroidal anti-inflammatory agents
comprise corticosteroids, glucocorticoids, cortisone, cortisone
acetate, hydrocortisone, hydrocortisone acetate, dexamethasone,
betamethasone, prednisone, prednisolone, methylprednisolone,
deltasone, triamcinolone, tixocortol pivalate, mometasone,
amcinonide, budesonide, desonide, fluociconide, fluocinolone,
halcinonide, fluocortolone, hydrocortisone-17-valerate,
halometasone, alclometasone dipropionate, betamethasone valerate,
betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate,
clobetasol-17-propionate, fluocortolone caproate, fluocortolone
pivalate, fluprednidene acetate, hydrocortisone-17-butyrate,
hydrocortisone-17-aceponate, hydrocortisone-17-buteprate,
ciclesonide, flunisolide, fluticasone furoate, fluticasone
propionate, triamcinolone acetonide, beclomethasone
dipropionate.
[0173] Suitable examples for non-steroidal anti-inflammatory drugs
(NSAIDs) comprise acetylsalicylic acid, salicylic acid and
salicylates, paracetamol (acetaminophen), salsalate, diflunisal,
ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen,
dexketoprofen, flurbiprofen, oxaprozin, loxoprofen, indomethacin,
tolmetin, sulindac, etodolac, ketorolac, diclofenac, aceclofenac,
nabumetone, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam,
isoxicam, phenylbutazone, mefenamic acid, meclofenamic acid,
flufenamic acid, tolfenamic acid, celexoxib, rofecoxib, valdecoxib,
parecoxib, lumiracoxib, etoricoxib, firocoxib, nimesulide,
clonixin, licofelone, H-harpagide, flunixin, tiaprofenic acid.
[0174] Suitable examples for immunomodulatory agents (IMIDs)
comprise thalidomide, lenalidomide, pomalidomide and
apremilast.
[0175] Suitable examples for antiviral agents comprise ancriviroc,
aplaviroc, cenicriviroc, enfuvirtide, maraviroc, vicriviroc,
amantadine, rimantadine, pleconaril, idoxuridine, aciclovir,
brivudine, famciclovir, penciclovir, sorivudine, valaciclovir,
cidofovir, ganciclovir, valganciclovir, sofosbusvir, foscarnet,
ribavirine, taribavirine, filibuvir, nesbuvir, tegobuvir,
fosdevirine, favipiravir, merimepodib, asunaprevir, balapiravir,
boceprevir, ciluprevir, danoprevir, daclatasvir, narlaprevir,
telaprevir, simeprevir, vaniprevir, rupintrivir, fomivirsen,
amenamevir, alisporivir, bevirimate, letermovir, laninamivir,
oseltamivir, peramivir, zanamivir.
[0176] Suitable examples for immunostimulatory agents comprise
interferons (.alpha.-, .beta.-, .gamma.-, .tau.-interferon),
interleukins, CSF, PDGF, EGF, IGF, THF, levamisol, dimepranol,
inosine.
[0177] Suitable examples for immunosuppressive agents comprise the
group of glucocorticoids, as described before; cytostatic agents
such as alkylating agents (such as cyclophosphamide),
Antimetabolites such as methotrexate, azathioprine, mercaptopurine,
fluorouracil, leflunomide, protein synthesis inhibitors and certain
antibiotics such as dactinomycine, anthracyclines, mitomycine C,
bleomycine and mithramycine, intercalating agents such as
mitoxantrone; antibodies such as muromonab-CD3, rituximab,
ustekinumab, alemtuzumab, natalizumab, basiliximab and daclizumab;
agents acting on immunophilins such as cyclosporine, tacrolimus and
sirolimus; and non-classified immunosuppressive agents such as
.beta.-interferon, .gamma.-interferon, opioids, TNF-binding
proteins such as infliximab, etanercept, adalimumab; or curcumin,
catechins, mycophenolic acid, fingolimod, myriocin and fumaric acid
dimethyl ester.
[0178] Suitable examples for antibiotics comprise imipenem,
meropenem, ertapenem, cephalosporins, aztreonam, penicillines such
as penicillin G and penicillin V, piperacillin, mezlocillin,
ampicillin, amoxicillin, flucloxacillin, methicillin, oxacillin,
clavulanic acid, sulbactam, tazobactam, sultamicillin, fosfomycine,
teicoplanin, vancomycin, bacitracin, colistine, gramicidin,
polymyxin B, tyrothricin, teixobactin, fosmidomycin, amikacin,
gentamicin, kanamycin, neomycin, netilmicin, streptomycin,
tobramycin, chloramphenicol, fusidinic acid, cethromycin,
narbomycin, telithromycin, clindamycin, lincomycin, daptomycin,
dalfopristin, quinupristin, azithromycin, clarithromycin,
erythromycin, roxithromycin, linezolid, doxycycline, minocycline,
tetracycline, oxytetracycline, tigecycline, norfloxacin, enoxacin,
ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin,
metronidazole, tinidazole, aminocumarine, sulfadiazine,
sulfadoxine, sulfamethoxazol, sulfasalazine, pyrimethamine,
trimethoprim, and rifampicin.
[0179] Anti-infective agents is a generic term for compounds used
in the treatment of bacterial, viral, fungal, protozoal and worm
infections and comprises antibiotics, antiviral agents,
antimycotics, antiprotozoal agents and anthelmintics.
[0180] Suitable examples for muscle relaxants comprise tercuronium,
1-ethylcarbamoyl-3-(3-trifluoromethylphenyl)pyrrolidine,
metaxalone, methocarbamol, meprobamate, baclofen, carisoprodol,
chlorzoxanzone, cyclobenzaprine, dantrolene, diazepam,
orphenadrine, quinine, rocuronium, succinylcholine, decamethonium,
pancuronium, veruronium, rapacuronium, dacuronium, duador,
malouetine, dipyrandium, pipercuronium, chandonium, HS-342,
atracurium, mivacurium, doxacurium, d-tubocurarine,
dimethyltubocurarine, gallamine, alcuronium, anatruxonium,
diadonium, fazadinium, tropeinium, cisatrucurium.
[0181] Suitable examples for antimycotics comprise abafungin,
amphotericin B, candicidin, filipin, hamycin, natamycin, nystatin,
rimocidin, bifonazole, butoconazole, clotrimazole, econazole,
fenticonazole, isoconazole, ketoconazole, luliconazole, miconazole,
omoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole,
albaconazole, efinaconazole, epoxiconazole, fluconazole,
isavuconazole, itraconazole, posaconazole, propiconazole,
ravuconazole, terconazole, voriconazole, amorolfine, butenafine,
nafitifine, terbinafine, anidulafungin, caspofungin, micafungin,
benzoic acid, ciclopirox, flucytosine, griseofulvin, haloprogin,
tolnaftate, undecylenic acid, crystal violet, Peru balm.
[0182] Suitable examples for antiprotozoal agents comprise
metronidazole, tinidazole, ornidazole, atovaquone, clioquinole,
chlorquinaldole, emetine, pentamidine isethionate, eflornithine,
nitrofural, halofuginone, miltefosine, chloroquine,
hydroxychloroquine, mepacrine, primaquine, amodiaquine, pamaquine,
piperaquine, proguanil, cyclohunail embonate, quinine, mefloquine,
pyrimethamine, artmether, artemisinine, artesunate,
dihydroartemisinine, halofantrine, lumefantrine, sulfadoxine.
[0183] Suitable examples for anthelmintics comprise mebendazole,
praziquantel, albendazole, diethylcarbamazine, flubendazole,
ivermectin, levamisole, metrifonate, niclosamide, oxyclozanide,
oxamniquine, oxantel, piperazine, pyrantel, pyrantel pamoate,
monopantel, derquantel, pelletierine sulfate, pyrvinium,
thiabendazole, fenbendazole, triclabendazole, abamectin, suramine,
emodepside, pyrvinium embonate, aminoacetonitrile.
[0184] Suitable examples for local anesthetics comprise lidocaine,
lignocaine, menthol, articaine, bupivacaine, ropivacaine,
benzocaine, chloroprocaine, cocaine, cyclomethycaine, dimethocaine,
larocaine, piperocaine, propoxycaine, procaine, novocaine,
proparacaine, tetracaine, amethocaine, cinchocaine, dibucaine,
etidocaine, levobupivacaine, meplavacaine, prilocaine, trimecaine,
saxitoxin, neosaxitoxin, tetrodotoxin, eugenol.
[0185] Suitable examples for analgesics comprise the NSAIDs listed
above; opioid analgesics such as morphine, fentanyl, methadone,
oxycodone, carfetanyl, dihydroetorphine, ohmefentanyl, etorphine,
sufentanil, remifentanil, alfentanil, buprenorphine, hydromorphone,
levomethadone, hydrocodone, pintramide, nalbuphine, tapentadol,
pentazocine, dihydrocodeine, codeine, pethidine, tramadol,
tilidine, meptazinol, naloxone, naltrexone, diprenorphine,
loperamide, apomorphine; epibatidine; scopolamine; ziconitide;
cannabinoids such as tetrahydrocannabinol, cannabidiol, marinol;
flupirtine; ketamine and the local anesthetics listed above.
[0186] Suitable examples for anticoagulants comprise heparins,
coumarins such as phenprocoumon (Marcumar) and warfarin, apixaban,
rivaroxaban, edoxaban, dabigatran, ximelagatran, hirudin,
lepirudine, bivalirudine, citrate, EDTA, fondaparinux, argatroban,
otamixaban.
[0187] Suitable examples for thrombocyte aggregation inhibitors
comprise abciximab, acetylsalicylic acid, dipyridamole,
clopidogrel, eptifibatide, ilomedine, prostacyclin, prasugrel,
ticagrelor, ticlopidine, tirofiban.
[0188] Tonic agents is a generic term for active ingredients that
strengthen the body, augment the tonus or restore its physiological
functions. They may be of herbal or animal origin.
[0189] Anabolic agents may support the anabolic metabolism and a
strengthening of the cellular collagen scaffold. However, a wide
abuse of these substances for doping in sports and bodybuilding is
known. Hence, a combination with the crystalline Form III of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt is only
recommended insofar this is covered by the respective national
legislations.
[0190] Standard therapies for the aforementioned active ingredients
can be easily found in the art by a skilled person. It is preferred
that the respective application forms and doses of the
aforementioned combinations of active ingredients follow the
already established standard therapies for the combinational active
ingredient besides the inventive crystalline Form III of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt.
Abbreviations:
TABLE-US-00005 [0191] vol % percent by volume fig. figure ca. circa
cm.sup.-1 wave-number cm.sup.3 cubic centimeter DMSO dimethyl
sulfoxide FT-IR Fourier-Transformation Infrared g gram wt % percent
by weight (mass fraction) GMP Good Manufacturing Practice GPP Good
Pharmacy Practice h hour H.sub.2O water IL interleukin kg kilogram
l liter LPS lipopolysaccharides m.sup.3 cubic meter mbar millibar
mg milligram mL milliliter mmol millimol mol mol nm nanometer pg
pikogram PMA phorbol 12-myristate 13-acetate SEM scanning electron
microscope RT room temperature s standard deviation TNF tumor
necrosis factor a.o. amongst others fd fully demineralized cf.
confer XRPD X-ray powder diffractogram e.g. exempli gratia
SHORT DESCRIPTION OF THE FIGURES
[0192] FIG. 1 describes a powder diffractogram of crystalline form
III according to the invention, wherein FIG. 1a displays the plot
of the Rietveld refinement over the full recorded range from
3-80.085 .degree.2.theta., whereas FIG. 1b displays a section of
the plot within the range of 3-35 .degree.2.theta.
[0193] FIG. 2 displays a comparative presentation of the packing
motifs in the crystal structures of forms I and II as well as of
form III according to the invention in the respective direction of
the unit cell axes, illustrated as ball-and-stick model and as
calotte model.
[0194] FIG. 2a shows the a-axis in the ball-and-stick model,
[0195] FIG. 2b shows the a-axis in the calotte model,
[0196] FIG. 2c shows the b-axis in the ball-and-stick model,
[0197] FIG. 2d shows the b-axis in the calotte model,
[0198] FIG. 2e shows the c-axis in the ball-and-stick model,
[0199] FIG. 2f shows the a-axis in the calotte model.
[0200] FIG. 3 displays a solid state FT-IR spectrum of form III
according to the invention, wherein FIG. 3a displays the plot over
the full recorded range from 4000-400 cm.sup.-1, whereas FIG. 3b
displays a section of the plot within the range of 1800-400
cm.sup.-1.
[0201] FIG. 4 displays a Raman spectrum of form III within the
range of 90-1800 cm.sup.-1.
[0202] FIG. 5 displays SEM recordings of forms I and II, as well as
of form III according to the invention.
[0203] FIG. 5a shows a comparative presentation of all three forms
in 2,500.times. magnification.
[0204] FIG. 5b shows a comparative presentation of the very similar
forms II and III in 1,000.times., 10,000.times., 25,000.times. and
50,000.times. magnification.
[0205] FIG. 6: Powder diffractograms of suspensions of a 50:50 wt %
mixture of forms II and III in 2-propanol, ethanol and methanol
after equilibration for 24 h (FIG. 6a), respectively of a 50:50 wt
% mixture of forms I and III in 2-propanol, ethanol and methanol
after equilibration for 3 days (FIG. 6b). For comparison a
diffractogram of the respective starting mixtures is shown as
well.
[0206] In FIG. 6a singular reflexes for form III with increasing
intensities are highlighted by arrows. (|) show the reflection
positions of the respective form.
[0207] In FIG. 6b singular reflexes for form I with decreasing
intensities are highlighted by arrows. (|) show the reflection
positions of the respective form.
[0208] FIG. 7 displays the secretion of the cytokines TNF alpha and
IL-6 of differentiated HL60 cells in pg/mL after respective
pre-stimulation for 1 h with
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt dihydrate, the
anhydrate forms I, II and III or a negative control and subsequent
stimulation with 100 ng/mL lipopolysaccharides (LPS) for 24 h (mean
is based on 3 measurements, respectively).
[0209] FIG. 7a shows the TNF alpha secretion of differentiated HL60
cells in pg/mL and
[0210] FIG. 7b shows the IL-6 secretion of differentiated HL60
cells in pg/mL.
[0211] FIG. 8 displays the solubility of
5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt in mol/l in a
DMSO-H.sub.2O mixture with an increasing proportion of H.sub.2O.
With an increasing proportion of H.sub.2O the solubility increases
continuously.
* * * * *
References